

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment

NCT06192563

Status RECRUITING
Sponsor Sanofi
Enrollment 150 participants

Key Eligibility Criteria

Inclusion (8)

- Male or female, aged between 12 and 17 years at the baseline visit
- Patients with AD who have been prescribed dupilumab according to Agenzia Italiana del Farmaco (AIFA) reimbursement criteria and fulfilling the following criteria:
- Patients with EASI < 16 and
- Children's Dermatology Life Quality Index (CDLQI) \geq 10 or
- Peak Pruritus Numerical Rating Scale (PP-NRS) \geq 7 or
- ... and 3 more (see full listing online)

Exclusion (4)

- Prior use of dupilumab within 6 months prior the study entry
- Patients currently participating in any interventional clinical trial which modifies patient care
- Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study (e.g., substance abuse)
- The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Locations (9 total)

Investigational Site Number: 002, Bologna, Italy
Investigational Site Number: 006, Brescia, Italy
Investigational Site Number: 004, Florence, Italy
... and 6 more locations